Axsome therapeutics presents positive pivotal phase 3 results of the accord-2 trial of axs-05 in alzheimer's disease agitation and the symphony trial of axs-12 in narcolepsy at the 2025 american academy of neurology (aan) annual meeting

Late-breaking oral presentation of results from the positive pivotal accord-2 phase 3 trial of axs-05 in alzheimer's disease agitation

AAN Ratings Summary

AAN Quant Ranking